IL2 and neoplasm: Here, we show that Ad5/3-E2F-d24-vIL2 is a promising candidate to overcome two main caveats that have restricted the clinical use of wt IL-2 cytokine therapy: low therapeutic levels in the tumor lesion, and severe systemic toxicity (7, 31).